Silence Therapeutics Plc logo

Silence Therapeutics Plc Share Price Today

(NASDAQ: SLN)

Silence Therapeutics Plc share price is $4.73 & ₹411.82 as on 6 Mar 2025, 2.30 'hrs' IST

$4.73

0.25

(5.58%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Silence Therapeutics Plc share price in Dollar and Rupees. Guide to invest in Silence Therapeutics Plc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Silence Therapeutics Plc, along with analyst recommendations, forecasts, and comprehensive financials.

Silence Therapeutics Plc share price movements

  • Today's Low: $4.18
    Today's High: $4.73

    Day's Volatility :11.57%

  • 52 Weeks Low: $4.06
    52 Weeks High: $27.72

    52 Weeks Volatility :85.35%

Silence Therapeutics Plc (SLN) Returns

PeriodSilence Therapeutics PlcSector (Health Care)Index (Russel 2000)
3 Months
-41.96%
3.7%
0.0%
6 Months
-74.91%
-2.8%
0.0%
1 Year
-81.06%
2.5%
0.0%
3 Years
-71.96%
12.9%
-11.6%

Silence Therapeutics Plc (SLN) Key Statistics

in dollars & INR

Previous Close
$4.48
Open
$4.46
Today's High
$4.73
Today's Low
$4.1828
Market Capitalization
$222.9M
Today's Volume
$152.3K
52 Week High
$27.72
52 Week Low
$4.06
Revenue TTM
$16.2M
EBITDA
$-58.0M
Earnings Per Share (EPS)
$-1.7
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-102.8%

How to invest in Silence Therapeutics Plc Stock (SLN) from India?

It is very easy for Indian residents to invest directly in Silence Therapeutics Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Silence Therapeutics Plc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Silence Therapeutics Plc or SLN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Silence Therapeutics Plc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Silence Therapeutics Plc shares which would translate to 0.184 fractional shares of Silence Therapeutics Plc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Silence Therapeutics Plc, in just a few clicks!

Returns in Silence Therapeutics Plc (SLN) for Indian investors in Rupees

The Silence Therapeutics Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Silence Therapeutics Plc investment value today

Current value as on today

₹24,000

Returns

₹76,000

(-76%)

Returns from Silence Therapeutics Plc Stock

₹81,065 (-81.06%)

Dollar Returns

₹5,065 (+5.06%)

Indian investors sentiment towards Silence Therapeutics Plc (SLN)

-20%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Silence Therapeutics Plc Stock from India on INDmoney has decreased by -20% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Silence Therapeutics Plc

  • TCG Crossover Management, LLC

    6.43%

  • Siren, L.L.C.

    6.00%

  • Redmile Group, LLC

    5.08%

  • Lombard Odier Asset Management USA Corp

    3.93%

  • Morgan Stanley - Brokerage Accounts

    3.52%

  • Vivo Capital, LLC

    2.34%

Analyst Recommendation on Silence Therapeutics Plc

Buy

    100%Buy

    0%Hold

    0%Sell

Based on 3 Wall street analysts offering stock ratings for Silence Therapeutics Plc(by analysts ranked 0 to 5 stars)

Analyst Forecast on Silence Therapeutics Plc Stock (SLN)

What analysts predicted

Upside of 891.18%

Target:

$46.88

Current:

$4.73

Insights on Silence Therapeutics Plc Stock (Ticker Symbol: SLN)

  • Price Movement

    In the last 3 months, SLN stock has moved down by -44.5%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 598.0K → 1.14M (in $), with an average increase of 47.6% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -1.87M → -27.01M (in $), with an average decrease of 401.6% per quarter
  • SLN vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 147.6%
  • SLN vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 123.8%
  • Price to Sales

    ForSLN every $1 of sales, investors are willing to pay $12.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

SLN Silence Therapeutics Plc Financials in INR & Dollars

FY19Y/Y Change
Revenue
$319.5K
-
Net Income
$-25.6M
↑ 6.36%
Net Profit Margin
-8.0K%
-
FY20Y/Y Change
Revenue
$7.4M
↑ 2145.49%
Net Income
$-43.7M
↑ 66.21%
Net Profit Margin
-594.03%
↑ 7431.38%
FY21Y/Y Change
Revenue
$16.5M
↑ 126.59%
Net Income
$-52.4M
↑ 21.09%
Net Profit Margin
-317.44%
↑ 276.59%
FY22Y/Y Change
Revenue
$21.3M
↑ 40.97%
Net Income
$-49.3M
↑ 2.74%
Net Profit Margin
-231.35%
↑ 86.09%
FY23Y/Y Change
Revenue
$32.1M
↑ 44.99%
Net Income
$-54.8M
↑ 6.86%
Net Profit Margin
-170.51%
↑ 60.84%
FY24Y/Y Change
Revenue
$43.3M
↑ 70.47%
Net Income
$-45.3M
↑ 4.72%
Net Profit Margin
-104.74%
↑ 65.77%
Q2 FY23Q/Q Change
Revenue
$11.5M
↓ 19.96%
Net Income
$-13.1M
↑ 1.93%
Net Profit Margin
-114.25%
↓ 24.54%
Q3 FY23Q/Q Change
Revenue
$3.5M
↓ 69.27%
Net Income
$-10.2M
↓ 20.68%
Net Profit Margin
-294.85%
↓ 180.6%
Q4 FY23Q/Q Change
Revenue
$2.7M
↓ 24.98%
Net Income
$-18.2M
↑ 74.69%
Net Profit Margin
-686.61%
↓ 391.76%
Q1 FY24Q/Q Change
Revenue
$15.8M
↑ 491.04%
Net Income
$-2.4M
↓ 86.98%
Net Profit Margin
-15.12%
↑ 671.49%
Q2 FY24Q/Q Change
Revenue
$760.0K
↓ 95.18%
Net Income
$-19.8M
↑ 729.53%
Net Profit Margin
-2.6K%
↓ 2587.22%
Q3 FY24Q/Q Change
Revenue
$1.1M
↑ 90.97%
Net Income
$-27.0M
↑ 73.58%
Net Profit Margin
-2.4K%
↑ 237.02%
FY19Y/Y Change
Profit
$319.5K
-
FY20Y/Y Change
Profit
$2.3M
↑ 603.69%
FY21Y/Y Change
Profit
$6.6M
↑ 188.82%
FY22Y/Y Change
Profit
$8.1M
↑ 33.51%
FY23Y/Y Change
Profit
$19.1M
↑ 127.41%
FY24Y/Y Change
Profit
$31.4M
↑ 108.86%
Q2 FY23Q/Q Change
Profit
$7.9M
↓ 8.29%
Q3 FY23Q/Q Change
Profit
$1.5M
↓ 81.01%
Q4 FY23Q/Q Change
Profit
$953.3K
↓ 36.78%
Q1 FY24Q/Q Change
Profit
$13.0M
↑ 1253.65%
Q2 FY24Q/Q Change
Profit
$-2.6M
↓ 120.01%
Q3 FY24Q/Q Change
Profit
$-1.6M
↓ 20.0%
FY19Y/Y Change
Operating Cash Flow
$2.3M
↓ 110.3%
Investing Cash Flow
$-19.7M
↑ 210.87%
Financing Cash Flow
$6.9M
↑ 1446.33%
FY20Y/Y Change
Operating Cash Flow
$-14.5M
↓ 723.97%
Investing Cash Flow
$12.9M
↓ 164.06%
Financing Cash Flow
$20.7M
↑ 192.58%
FY21Y/Y Change
Operating Cash Flow
$9.1M
↓ 163.16%
Investing Cash Flow
$11.5M
↓ 9.79%
Financing Cash Flow
$40.9M
↑ 99.06%
FY22Y/Y Change
Operating Cash Flow
$-55.3M
↓ 767.88%
Investing Cash Flow
$-20.1M
↓ 290.66%
Financing Cash Flow
$52.4M
↑ 40.17%
Q2 FY23Q/Q Change
Operating Cash Flow
$-18.9M
↑ 95.35%
Investing Cash Flow
$-5.9M
↑ 0.0%
Financing Cash Flow
$4.0M
↑ 16657.89%

Silence Therapeutics Plc Technicals Summary

Sell

Neutral

Buy

Silence Therapeutics Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Silence Therapeutics Plc (SLN) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Silence Therapeutics Plc logo
-15.69%
-74.91%
-81.06%
-71.96%
-80.34%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Silence Therapeutics Plc logo
NA
NA
NA
-0.85
-1.03
-0.27
NA
2.0
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Silence Therapeutics Plc logo
Buy
$222.9M
-80.34%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Silence Therapeutics Plc

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Organization
Silence Therapeutics Plc
Employees
0
CEO
Mr. Craig A. Tooman M.B.A.
Industry
Health Technology

Management People of Silence Therapeutics Plc

NameTitle
Mr. Craig A. Tooman M.B.A.
President, CEO & Executive Director
Ms. Rhonda L. Hellums
Executive VP, CFO & Secretary
Dr. Steven J. Romano M.D.
Executive VP and Chief Research & Development Officer
Dr. Marie Wikstrom Lindholm Ph.D.
Chief Scientific Officer
Ms. Gem Gokmen Hopkins
Head of IR & Corporate Communications
Ms. Gianine Esposito
Chief Human Resources Officer
Dr. Barbara A. Ruskin J.D., Ph.D.
Senior VP and Chief Intellectual Property & Innovation Officer
Mr. J.P. Gabriel
Chief Technical Operations Officer
Mr. Curtis Rambaran M.D.
Chief Medical Officer

Important FAQs about investing in SLN Stock from India :

What is Silence Therapeutics Plc share price today?

Silence Therapeutics Plc share price today stands at $4.73, Open: $4.46 ; Previous Close: $4.48 ; High: $4.73 ; Low: $4.18 ; 52 Week High: $27.72 ; 52 Week Low: $4.06.

The stock opens at $4.46, after a previous close of $4.48. The stock reached a daily high of $4.73 and a low of $4.18, with a 52-week high of $27.72 and a 52-week low of $4.06.

Can Indians buy Silence Therapeutics Plc shares?

Yes, Indians can invest in the Silence Therapeutics Plc (SLN) from India.

With INDmoney, you can buy Silence Therapeutics Plc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Silence Therapeutics Plc at zero transaction cost.

How can I buy Silence Therapeutics Plc shares from India?

It is very easy to buy Silence Therapeutics Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Silence Therapeutics Plc (SLN) be purchased?

Yes, you can buy fractional shares of Silence Therapeutics Plc with INDmoney app.

What are the documents required to start investing in Silence Therapeutics Plc stocks?

To start investing in Silence Therapeutics Plc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Silence Therapeutics Plc Stock (SLN)?

Today’s highest price of Silence Therapeutics Plc (SLN) is $4.73.

Today’s lowest price of Silence Therapeutics Plc (SLN) is $4.18.

What is today's market capitalisation of Silence Therapeutics Plc?

Today's market capitalisation of Silence Therapeutics Plc SLN is 222.9M

What is the 52 Week High and Low Range of Silence Therapeutics Plc Stock (SLN)?

  • 52 Week High

    $27.72

  • 52 Week Low

    $4.06

What are the historical returns of Silence Therapeutics Plc (SLN)?

  • 1 Month Returns

    -15.69%

  • 3 Months Returns

    -74.91%

  • 1 Year Returns

    -81.06%

  • 5 Years Returns

    -80.34%

Who is the Chief Executive Officer (CEO) of Silence Therapeutics Plc ?

Mr. Craig A. Tooman M.B.A. is the current Chief Executive Officer (CEO) of Silence Therapeutics Plc.